Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy
Authors
Keywords
-
Journal
Frontiers in Endocrinology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-05-19
DOI
10.3389/fendo.2021.679000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) M. Pavel et al. ANNALS OF ONCOLOGY
- Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
- (2020) Jason S Starr et al. OncoTargets and Therapy
- Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis
- (2020) Matteo Bauckneht et al. Diagnostics
- Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
- (2019) Anna Kathrin Stueven et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- From Bench to Bedside—The Bad Berka Experience With First-in-Human Studies
- (2019) Jingjing Zhang et al. SEMINARS IN NUCLEAR MEDICINE
- Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety
- (2019) Sanjana Ballal et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies
- (2018) Lingaku Lee et al. Expert Review of Anticancer Therapy
- The evolution of surgical strategies for pancreatic neuroendocrine tumors (Pan-NENs): Time-trend and outcome analysis from 587 consecutive resections
- (2018) Giovanni Marchegiani et al. PANCREATOLOGY
- Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors – a multi-institutional study
- (2018) Ville J. Sallinen et al. HPB
- Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review
- (2018) D. Magalhães et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
- (2018) Thomas Günther et al. PHARMACOLOGICAL REVIEWS
- Radioguided Surgery With Gallium 68 Dotatate for Patients With Neuroendocrine Tumors
- (2018) Mustapha El Lakis et al. JAMA Surgery
- Patterns of recurrence after resection for pancreatic neuroendocrine tumors: who, when, and where?
- (2018) Giovanni Marchegiani et al. NEUROENDOCRINOLOGY
- Systematic review of current prognostication systems for pancreatic neuroendocrine neoplasms
- (2018) Roxanne Y.A. Teo et al. SURGERY
- Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications
- (2017) Elettra Merola et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pancreatic neuroendocrine tumors: A population-based analysis of epidemiology and outcomes.
- (2017) Samer Alsidawi et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatostatin Receptor Antagonists for Imaging and Therapy
- (2017) Melpomeni Fani et al. JOURNAL OF NUCLEAR MEDICINE
- 68 Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis
- (2017) Michael M. Graham et al. JOURNAL OF NUCLEAR MEDICINE
- The Impact of Somatostatin Receptor–Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis
- (2017) Martin Barrio et al. JOURNAL OF NUCLEAR MEDICINE
- Safety, Biodistribution, and Radiation Dosimetry of68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study
- (2017) Guillaume P. Nicolas et al. JOURNAL OF NUCLEAR MEDICINE
- Sensitivity Comparison of68Ga-OPS202 and68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study
- (2017) Guillaume P. Nicolas et al. JOURNAL OF NUCLEAR MEDICINE
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging
- (2017) Anders Sundin et al. NEUROENDOCRINOLOGY
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy
- (2017) Ho Sze Chan et al. PLoS One
- Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors
- (2017) Yuhong Wang et al. Oncology Letters
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
- (2017) Arvind Dasari et al. JAMA Oncology
- Gastroenteropancreatic neuroendocrine tumours (GEP-NET) – Imaging and staging
- (2016) Tobias Baumann et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
- (2016) Martyn E Caplin et al. ENDOCRINE-RELATED CANCER
- The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors
- (2016) Philippe Brunner et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies
- (2016) Tetsuhide Ito et al. EXPERT OPINION ON PHARMACOTHERAPY
- Pathologic Classification of Neuroendocrine Neoplasms
- (2016) David S. Klimstra HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
- (2016) Alexandria T. Phan et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites
- (2016) Samira M. Sadowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of the Impact of 68 Ga-DOTATATE and 18 F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors
- (2016) Emmanouil Panagiotidis et al. JOURNAL OF NUCLEAR MEDICINE
- Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors
- (2016) S. A. Deppen et al. JOURNAL OF NUCLEAR MEDICINE
- 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
- (2016) S. A. Deppen et al. JOURNAL OF NUCLEAR MEDICINE
- ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors
- (2016) M. Falconi et al. NEUROENDOCRINOLOGY
- ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
- (2016) M. Pavel et al. NEUROENDOCRINOLOGY
- ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
- (2016) R. Garcia-Carbonero et al. NEUROENDOCRINOLOGY
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival
- (2016) Anja Rinke et al. NEUROENDOCRINOLOGY
- Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors
- (2016) Ki Byung Song et al. PANCREAS
- Molecular imaging in neuroendocrine tumors
- (2016) Tetsuhide Ito et al. Current Opinion in Endocrinology Diabetes and Obesity
- Imaging of neuroendocrine tumors of the pancreas
- (2016) C. Dromain et al. Diagnostic and Interventional Imaging
- The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms
- (2015) Olca Basturk et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Feasibility of Radio-Guided Surgery with 68Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors
- (2015) Samira M. Sadowski et al. ANNALS OF SURGICAL ONCOLOGY
- Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours
- (2015) S. Van Binnebeek et al. EUROPEAN RADIOLOGY
- Pasireotide for malignant insulinoma
- (2015) Amit Tirosh et al. Hormones-International Journal of Endocrinology and Metabolism
- Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas
- (2015) V. Ambrosini et al. JOURNAL OF NUCLEAR MEDICINE
- The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom
- (2015) E. Skoura et al. JOURNAL OF NUCLEAR MEDICINE
- Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models
- (2015) S. U. Dalm et al. JOURNAL OF NUCLEAR MEDICINE
- Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors
- (2015) Shreya Mehta et al. MEDICINE
- Therapeutic uses of somatostatin and its analogues: Current view and potential applications
- (2015) Uma Rai et al. PHARMACOLOGY & THERAPEUTICS
- Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes
- (2014) Julie Hallet et al. CANCER
- Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations
- (2014) Omar Abdel-Rahman et al. ENDOCRINE-RELATED CANCER
- Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors
- (2014) M Cives et al. ENDOCRINE-RELATED CANCER
- Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor
- (2014) Punit Sharma et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours
- (2014) Samer Ezziddin et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
- (2014) C. Kratochwil et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature
- (2014) Camilla Bardram Johnbeck et al. Future Oncology
- Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study
- (2014) D. Wild et al. JOURNAL OF NUCLEAR MEDICINE
- 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-Octreotide SPECT/CT, and Whole-Body MR Imaging in Detection of Neuroendocrine Tumors: A Prospective Trial
- (2014) E. C. S. d. C. Etchebehere et al. JOURNAL OF NUCLEAR MEDICINE
- SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors
- (2014) C. Kratochwil et al. MOLECULAR IMAGING AND BIOLOGY
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
- (2014) Martyn E. Caplin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis
- (2013) Jigang Yang et al. ACTA RADIOLOGICA
- Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes
- (2013) Kosuke Okuwaki et al. CANCER
- Zollinger–Ellison syndrome
- (2013) Tetsuhide Ito et al. CURRENT OPINION IN GASTROENTEROLOGY
- Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors
- (2013) D. Wild et al. JOURNAL OF NUCLEAR MEDICINE
- Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification
- (2013) I. Velikyan et al. JOURNAL OF NUCLEAR MEDICINE
- Neuroendocrine tumours: the role of imaging for diagnosis and therapy
- (2013) Martijn van Essen et al. Nature Reviews Endocrinology
- Impact of Octreotide Long-Acting Release on Tumour Growth Control as a First-Line Treatment in Neuroendocrine Tumours of Pancreatic Origin
- (2013) H. Jann et al. NEUROENDOCRINOLOGY
- Update on the Role of Somatostatin Analogs for the Treatment of Patients With Gastroenteropancreatic Neuroendocrine Tumors
- (2013) Christos Toumpanakis et al. SEMINARS IN ONCOLOGY
- Staging of neuroendocrine tumours: comparison of [68Ga]DOTATOC multiphase PET/CT and whole-body MRI
- (2013) C. Schraml et al. CANCER IMAGING
- Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study
- (2012) Larry K Kvols et al. ENDOCRINE-RELATED CANCER
- Improved Control of Severe Hypoglycemia in Patients with Malignant Insulinomas by Peptide Receptor Radionuclide Therapy
- (2011) E. van Schaik et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
- (2011) Anna Imhof et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiopeptide Imaging and Therapy in Europe
- (2011) V. Ambrosini et al. JOURNAL OF NUCLEAR MEDICINE
- First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible
- (2011) D. Wild et al. JOURNAL OF NUCLEAR MEDICINE
- An overview of targeted alpha therapy
- (2011) Young-Seung Kim et al. TUMOR BIOLOGY
- 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy
- (2010) Michael Garkavij et al. CANCER
- Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas
- (2010) Simona Grozinsky-Glasberg et al. CANCER
- Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy
- (2010) Samer Ezziddin et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Standardized Uptake Values of 68Ga-DOTANOC PET: A Promising Prognostic Tool in Neuroendocrine Tumors
- (2010) D. Campana et al. JOURNAL OF NUCLEAR MEDICINE
- Profiling of Somatostatin Receptor Subtype Expression by Quantitative PCR and Correlation With Clinicopathological Features in Pancreatic Endocrine Tumors
- (2010) Yoshihito Nakayama et al. PANCREAS
- Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours
- (2009) V. Zamora et al. DIGESTIVE AND LIVER DISEASE
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- Diagnosis and Treatment of Pancreatic Vasoactive Intestinal Peptide Endocrine Tumors
- (2009) Shaowei Song et al. PANCREAS
- Preclinical Evaluation of the -Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors
- (2008) M. Miederer et al. CLINICAL CANCER RESEARCH
- Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors
- (2008) David C. Metz et al. GASTROENTEROLOGY
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- (2008) Dik J. Kwekkeboom et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastroenteropancreatic neuroendocrine tumours
- (2008) Irvin M Modlin et al. LANCET ONCOLOGY
- Pasireotide (SOM230): Development, mechanism of action and potential applications
- (2007) Herbert A. Schmid MOLECULAR AND CELLULAR ENDOCRINOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started